Clinical Trials Logo

EGFR-TKI Resistant Mutation clinical trials

View clinical trials related to EGFR-TKI Resistant Mutation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02575560 Completed - Clinical trials for EGFR-TKI Resistant Mutation

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

Start date: October 1, 2015
Phase: N/A
Study type: Observational

EGFR-TKI is the main is the first line therapy for local advanced or metastatic non-small cell lung cancer with EGFR gene mutation. The median progression free survival time is around 11 months with the first generation EGFR-TKI. Patients with acquired resistance with first generation EGFR-TKI usually with EGFR exon 20 mutation (T790M). Change the drug administration maybe prolong patients PFS and evently prolong OS.